查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1609996

非酒精性脂肪性肝炎治療市場規模、佔有率、趨勢分析報告：按藥物、階段、分銷管道、地區和細分市場預測，2025-2030年

Non-alcoholic Steatohepatitis Treatment Market Size, Share & Trends Analysis Report By Drug (Vitamin E & Pioglitazone, Resmetirom), By Disease Stage, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

非酒精性脂肪性肝炎治療市場的成長與趨勢

Grand View Research, Inc.最新報告預測，到2030年，全球非酒精性脂肪性肝炎（NASH）治療市場規模將達到338億美元，2025年至2030年複合年成長率為28.1%。非酒精性脂肪性肝炎治療市場主要由諾和諾德的 Ozempic、Intercept 的 Ocaliva 和 Inventiva 的 Lanifibranor 等藥物的推出所推動。

未滿足的需求 由於缺乏核准的治療方法、高疾病負擔和診斷程序的複雜性等因素，市場上存在大量未滿足的需求。目前，市場以PIOGLITAZONE和維生素E等仿單標示外藥物為主。然而，為了抓住未得到滿足的機會，主要市場參與企業正在大力投資研發工作，以開發治療 NASH 的新療法。目前有 50 多個候選管道。

計劃在預測期內推出的後期候選藥物包括 Inventiva Pharma 的 Lanifibranor、Intercept Pharmaceuticals 的 Oveticholic Acid、Galmed Pharmaceuticals Ltd. 的 Aramchol、Novo Nordisk A/S 的 Semaglutide 和 Madrigal Pharmaceuticals, Inc. Resmetirom 等。其中，Intercept Pharmaceuticals 的奧貝膽酸 (OCA) 和 Madrigal Pharmaceuticals, Inc. 的 resmetirom 是最熱門的藥物，與其他候選藥物相比，預計將較早進入市場。

研究表明，非酒精性脂肪性肝炎與肥胖和糖尿病密切相關。研究表明，大約 80% 的 NASH 患者患有肥胖症。根據CDC 2021年最新統計數據，在美國等國家，肥胖盛行率高達42%。此外，美國和日本等國家是全球非酒精性脂肪肝炎盛行率最高的國家，這些國家的肥胖和糖尿病負擔也很高。所有這些因素預計將在整個預測期內推動 NASH 治療市場的發展。

製藥巨頭的策略性舉措和簡審類等監管支援措施預計將進一步加速市場成長。 2022年5月，輝瑞的erbogastat/creasacostat聯合治療獲得簡審類。這是一種治療非酒精性脂肪性肝炎的潛在藥物組合。此類藥物指定促進了藥物的臨床測試過程。

肝臟切片切片檢查是診斷非酒精性脂肪性肝炎的黃金標準。由於這種診斷測試是侵入性的，因此僅限於有症狀的病例，導致 NASH 的全球平均診斷率約為 20%。無法使用基於生物標記的非侵入性診斷非酒精性脂肪性肝炎的測試預計將阻礙市場成長。

非酒精性脂肪性肝炎治療市場報告亮點

  • 維生素 E 和PIOGLITAZONE（仿單標示外）是 2024 年市場佔有率達到 100% 的唯一貢獻者。這是由於市場上沒有核准的藥物。
  • 2024年，零售和專業藥品領域佔63.8%的佔有率。零售和專業藥局非常適合治療 NASH 等慢性疾病，因為患者通常在居家醫療環境中。
  • 北美在整個 NASH 治療領域的銷售中佔據主導地位。這是由於對該疾病的認知提高、醫療設施更好以及治療率比其他地區相對較高。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章非酒精性脂肪性肝炎治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 非酒精性脂肪性肝炎治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 管道分析

第4章非酒精性脂肪性肝炎治療市場：按藥物估計和趨勢分析

  • 細分儀表板
  • 全球非酒精性脂肪性肝炎治療市場：藥物波動分析
  • 按藥品分類的收益
  • 支氣管擴張劑
  • 奧貝膽酸 (OCA)
  • 雷尼非那醇
  • Semaglutide
  • 瑞美替隆
  • 阿蘭契爾
  • 阿蘭契爾
  • 塞尼克里比岩
  • 其他

第5章非酒精性脂肪性肝炎治療市場：分階段估計與趨勢分析

  • 細分儀表板
  • 全球非酒精性脂肪性肝炎治療市場：階段變化分析
  • 按疾病階段分類的收益
  • NASH F0 期
  • NASH F1 階段
  • NASH F2 期
  • NASH F3 期
  • NASH F3 期

第6章非酒精性脂肪性肝炎治療市場：依通路估算與趨勢分析

  • 細分儀表板
  • 全球非酒精性脂肪性肝炎治療市場：通路波動分析
  • 按分銷管道分類的收益
  • 醫院藥房
  • 零售/專業藥房
  • 其他藥局

第7章非酒精性脂肪肝炎治療市場：按產品、應用、最終用途、區域、估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 2024年主要企業市場佔有率分析
    • Intercept Pharmaceuticals, Inc.
    • Galmed Pharmaceuticals Ltd.
    • Inventiva.
    • AbbVie Inc.
    • Galectin Therapeutics Inc.
    • Madrigal Pharmaceuticals Inc（Madrigal）.
    • NGM Biopharmaceuticals, Inc.
    • Novo Nordisk A/S
    • The Bristol-Myers Squibb Company
    • Gilead Sciences, Inc.
Product Code: GVR-4-68039-964-6

Non-alcoholic Steatohepatitis Treatment Market Growth & Trends:

The global non-alcoholic steatohepatitis treatment market size is expected to reach USD 33.80 billion by 2030, registering a CAGR of 28.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The non-alcoholic steatohepatitis (NASH) treatment market is primarily driven by the launch of drugs such as Novo Nordisk's Ozempic, Intercept's Ocaliva, and Inventiva's lanifibranor, among others.

The NASH treatment market has major unmet needs owing to factors such as the unavailability of approved drugs, high disease burden, and complex diagnostic procedures. Currently, the market is dominated by off-label drugs such as Pioglitazone and Vitamin E. These are widely prescribed drugs in this space globally. However, to address the unmet opportunity, key market players are heavily investing in R&D activities to develop novel therapeutics for NASH treatment. Currently, there are more than 50 pipeline candidates.

Some of the late-stage pipeline candidates expected to launch during the forecast period include Inventiva Pharma's Lanifibranor, Intercept Pharmaceuticals' Obeticholic acid, Galmed Pharmaceuticals Ltd.'s Aramchol, Novo Nordisk A/S's Semaglutide, and Madrigal Pharmaceuticals, Inc.'s Resmetirom. Among these, Intercept Pharmaceuticals's Obeticholic Acid (OCA), and Madrigal Pharmaceuticals, Inc.'s Resmetirom, are the most looked upon drugs and are expected to enter comparatively earlier than other pipeline candidates.

Research studies reveal that non-alcoholic steatohepatitis is strongly associated with obesity and diabetes. Research studies show that around 80% of NASH patients are obese. In countries such as the U.S., the obesity prevalence is as high as 42%, according to the latest 2021 statistics by CDC. In addition, countries such as the U.S. and Japan account for the highest prevalence of non-alcoholic steatohepatitis globally, and these countries also have a high burden of obesity and diabetes. All such factors will fuel the NASH treatment market throughout the forecast period.

Strategic initiatives by pharma giants and supportive regulatory authority policies such as fast track designation are further expected to accelerate the market growth. In May 2022, Pfizer, Inc.'s Ervogastat/Clesacostat Combination therapy received fast track designation. This is one of the potential drug combinations for the treatment of non-alcoholic steatohepatitis. Such drug designation boosts the clinical trial process for drugs.

Liver biopsy is the gold standard for the diagnosis of non-alcoholic steatohepatitis. The invasive nature of this diagnostics test limits its usage to only symptomatic cases, and as a result, the global average diagnostic rate for NASH is around 20%. The unavailability of biomarkers-based non-invasive tests for the diagnosis of non-alcoholic steatohepatitis is expected to impede the market growth.

Non-alcoholic Steatohepatitis Treatment Market Report Highlights:

  • Vitamin E and Pioglitazone (Off-label) acted as the lone contributor with a 100% share of the market in 2024. This can be attributed to the unavailability of approved drugs in the market
  • The retail and specialty pharmacies segment held a share of 63.8% in 2024. Retail and specialty pharmacies are more compatible with chronic diseases such as NASH, where the patients are more commonly associated with homecare settings
  • North America dominated the overall NASH treatment space in terms of revenue. This can be attributed to increased disease awareness, better healthcare facilities, and comparatively higher treatment rate than in other regions

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Disease Stage
    • 1.2.3. Distribution channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug and disease stage outlook
    • 2.2.2. Distribution channel outlook
  • 2.3. Competitive Insights

Chapter 3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of Non-Alcoholic Steatohepatitis (NASH) disease
      • 3.2.1.2. Rising awareness about disease
      • 3.2.1.3. Robust product pipeline and rising R&D
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Stringent regulations
  • 3.3. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pipeline Analysis

Chapter 4. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Drug Movement Analysis
  • 4.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, By Drug, Revenue (USD Million)
  • 4.4. Bronchodilators
    • 4.4.1. Vitamin E and Pioglitazone market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Obeticholic Acid (OCA)
    • 4.5.1. Obeticholic Acid (OCA) market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Lanifibranor
    • 4.6.1. Lanifibranor market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. Semaglutide
    • 4.7.1. Semaglutide market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.8. Resmetirom
    • 4.8.1. Resmetirom market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.9. Aramchol
    • 4.9.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.10. Aramchol
    • 4.10.1. Aramchol market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.11. Cenicriviroc
    • 4.11.1. Cenicriviroc market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.12. Other Drugs
    • 4.12.1. Other drugs market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Disease Stage Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Disease Stage Movement Analysis
  • 5.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, By Disease Stage, Revenue (USD Million)
  • 5.4. NASH Stage F0
    • 5.4.1. NASH stage F0 market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. NASH Stage F1
    • 5.5.1. NASH stage F1 market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. NASH Stage F2
    • 5.6.1. NASH stage F2 market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. NASH Stage F3
    • 5.7.1. NASH stage F3 market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.8. NASH Stage F3
    • 5.8.1. NASH stage F3 market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Distribution Channel Movement Analysis
  • 6.3. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospitals Pharmacies
    • 6.4.1. Hospitals pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Retail and Specialty Pharmacies
    • 6.5.1. Retail and Specialty Pharmacies market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Other Pharmacies
    • 6.6.1. Other pharmacies market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Regional Estimates & Trend Analysis By Product, Application, and End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company market share analysis, 2024
    • 8.3.2. Intercept Pharmaceuticals, Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Galmed Pharmaceuticals Ltd.
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Inventiva.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. AbbVie Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Galectin Therapeutics Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Madrigal Pharmaceuticals Inc (Madrigal).
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. NGM Biopharmaceuticals, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Novo Nordisk A/S
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. The Bristol-Myers Squibb Company
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Gilead Sciences, Inc.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviation
  • Table 4 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
  • Table 5 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 6 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 7 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 8 U.S. Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 9 U.S. Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 10 U.S. Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 11 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 12 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Disease Stage, 2018 - 2030 (USD Million)
  • Table 13 Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 14 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 15 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market, by Disease Stage, 2018 - 2030 (USD Million)
  • Table 16 Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 17 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
  • Table 18 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 19 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 20 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 21 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 22 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 23 Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 24 UK Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 25 UK Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 26 UK Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 27 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 28 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 29 France Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 30 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 31 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 32 Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 33 Spain Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 34 Spain Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 35 Spain Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 36 Denmark Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 37 Denmark Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 38 Denmark Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 39 Sweden Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 40 Sweden Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 41 Sweden Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 42 Norway Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 43 Norway Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 44 Norway Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 49 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 50 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 51 Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 52 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 53 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 54 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 55 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 56 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 57 India Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 58 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 59 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 60 South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 61 Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 62 Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 63 Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 64 Thailand Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 65 Thailand Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 66 Thailand Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 67 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
  • Table 68 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 69 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 70 Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 71 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 72 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 73 Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 74 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 75 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 76 Argentina Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 77 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By region, 2018 - 2030 (USD Million)
  • Table 78 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 84 South Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 85 South Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 86 South Africa Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 87 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 88 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 89 UAE Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 90 Kuwait Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Drug, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Disease Stage, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Non-Alcoholic Steatohepatitis (NASH) Treatment Market, By Distribution Channel 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Non-Alcoholic steatohepatitis (NASH) treatment market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Non-alcoholic steatohepatitis (NASH) treatment market snapshot
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook, revenue, 2024 (USD Million)
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Non-alcoholic steatohepatitis (NASH) treatment market driver impact
  • Fig. 14 Non-alcoholic steatohepatitis (NASH) treatment market restraint impact
  • Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 16 Industry Analysis - Porter's Five Forces
  • Fig. 17 Strategy mapping
  • Fig. 18 Non-alcoholic steatohepatitis (NASH) treatment market: Drug outlook and key takeaways
  • Fig. 19 Non-alcoholic steatohepatitis (NASH) treatment market: Drug movement analysis & market share 2024 & 2030
  • Fig. 20 Vitamin E and Pioglitazone non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Obeticholic Acid non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Lanifibranor non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Semaglutide non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Resmetirom non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Aramchol non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Cenicriviroc non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Other drugs non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Non-alcoholic steatohepatitis (NASH) treatment market: Disease stage outlook and key takeaways
  • Fig. 29 Non-alcoholic steatohepatitis (NASH) treatment market: Disease stage movement analysis & market share 2024 & 2030
  • Fig. 30 NASH F0 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 NASH F1 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 NASH F2 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 NASH F3 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 NASH F4 non-alcoholic steatohepatitis (NASH) treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Non-alcoholic steatohepatitis (NASH) treatment market: Distribution channel outlook and key takeaways
  • Fig. 36 Non-alcoholic steatohepatitis (NASH) treatment market: Distribution channel movement analysis & market share 2024 & 2030
  • Fig. 37 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Retail and specialty pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Other pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Global Non-Alcoholic Steatohepatitis (NASH) Treatment market: Regional movement analysis
  • Fig. 41 Global Non-Alcoholic Steatohepatitis (NASH) Treatment market: Regional outlook and key takeaways
  • Fig. 42 Global Non-Alcoholic Steatohepatitis (NASH) Treatment market share and leading players
  • Fig. 43 North America, by country
  • Fig. 44 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. key country dynamics
  • Fig. 46 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Canada key country dynamics
  • Fig. 48 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico key country dynamics
  • Fig. 50 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 UK key country dynamics
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Germany key country dynamics
  • Fig. 55 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 France key country dynamics
  • Fig. 57 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Italy key country dynamics
  • Fig. 59 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Spain key country dynamics
  • Fig. 61 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Denmark key country dynamics
  • Fig. 63 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Sweden key country dynamics
  • Fig. 65 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Norway key country dynamics
  • Fig. 67 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 China key country dynamics
  • Fig. 70 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Japan key country dynamics
  • Fig. 72 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 India key country dynamics
  • Fig. 74 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Thailand key country dynamics
  • Fig. 76 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 South Korea key country dynamics
  • Fig. 78 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Australia key country dynamics
  • Fig. 80 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Brazil key country dynamics
  • Fig. 83 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Argentina key country dynamics
  • Fig. 85 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 South Africa key country dynamics
  • Fig. 88 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Saudi Arabia key country dynamics
  • Fig. 90 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 UAE key country dynamics
  • Fig. 92 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Kuwait key country dynamics
  • Fig. 94 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Market share Analysis of key market players, 2024